In addition, ARID1A deficiency was associated with a higher TMB, more infiltrating lymphocytes, and increased PD-L1 expression in various tumours [20, 21].Moreover, mice with ARID1A-deficient ovarian cancers showed a prolonged survival rate when treated with ICBs [22]. This evidence concerns the gene ARID1A and ovarian carcinoma.